Innovative Healthcare
through Blood-based
Early Detection of Cancer 
Innovative Healthcare
through Blood-based
Early Detection of Cancer
Strengths of IMB Dx

First mover in the Liquid Biopsy CDx

Global top-tier Competitiveness in Sensitive LOD

High-Technology Expandability to
the Early Detection of Cancer

What We DO





Early Detection of
Cancer through blood

IMB Dx detects cancer by analyzing the
minute ctDNA (circulating tumor DNA).






Clinical Analysis Service
based on Genomics

Provides the customized service to analyze
genomics for research and clinic institute.






Customized B2B Gene
Analysis Service

IMB Dx looks for the new business
model to apply for our genomics.



What We DO

 AlphaLiquid®


The Liquid Biopsy of IMB Dx, AlphaLiquid, provides The Liquid Biopsy of 

IMB Dx provides targeted gene results that can help direct therapy 

selection and clinical trial options for advanced-stage cancer patients 

using an invasive way. By analyzing SNV, CNV, InDel, SV of ctDNA with 

our comprehensive genomic profiling approach and providing clinical 

reports, The Liquid Biopsy of IMB Dx empowers clinicians to make 

more informed clinical decisions even when tissue is not ideal.

 AlphaLiquid®

The Liquid Biopsy of IMB Dx, AlphaLiquid, provides targeted gene results that can help direct therapy selection and clinical trial options for advanced-stage cancer patients using an invasive way.

 

By analyzing SNV, CNV, InDel, SV of ctDNA with our comprehensive genomic profiling approach and providing clinical reports, The Liquid Biopsy of IMB Dx empowers clinicians to make more informed clinical decisions even when tissue is not ideal.

IMB Dx

Address : 20F, Bldg A, BYC Highcity, 131, Gasan digital 1-ro, Geumcheon-gu, Seoul, 08506, Korea

Tel : +82-26951-2906  ㅣ  Fax : +82-26947-3705  ㅣ  E-mail : info@imbdx.com

Copyright ⓒ IMB Dx, lnc.  All rights reserved.